UGT engineering for detoxifying anticancer drug SN-38
UGT engineering for detoxifying anticancer drug SN-38
批准号:
8879323
负责人:
Xiaoqiang Wang
金额:
$45.16万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-07 至 2019-03-31
关键词:
Adverse effectsAffectAminesAntineoplastic AgentsBacteriaBiological AssayColonDNADNA-Directed DNA PolymeraseDockingDrug Metabolic DetoxicationDrug usageEngineeringEnzymesEscherichiaEscherichia coliEstradiolFlavonoidsGlucuronosyltransferaseGoalsHealthHumanIn VitroLibrariesMedicago truncatulaMetabolismMethodologyMethodsModelingMolecularMusMutagenesisMutationNitrosaminesOralPharmaceutical PreparationsPhasePlantsProcessProtein EngineeringProteinsSN-38SeriesSiteStructureSystemToxinUGT1A1 geneUridine DiphosphateXenobioticsbacterial vectorbasechemotherapydesigndrug developmentengineering designenzyme activityglycosylationglycosyltransferaseimprovedin vivoinsertion/deletion mutationmutantoverexpressionprotein expressionpublic health relevancescreeningsmall moleculevectorwasting
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There are often serious side effects for anti-cancer drugs used in chemotherapy. Usually only small portion of drug is delivered to the target sites, and others may become waste or even toxic for humans. Uridine diphosphate (UDP) glycosyltransferases (UGTs) are the central players in the glycosylation of small molecules including toxins and drugs, and are key phase II drug metabolizing enzymes in human. Human UDP-glucuronosyltransferase 1A1 is responsible for elimination and detoxification of structurally diverse groups of xenobiotics (e.g., SN-38, polycyclic amines and nitrosamines) and endogenous compounds. We found that plant Medicago truncatula UGT71G1 could also efficiently metabolize typical human UGT1A1 substrates including SN-38 and estradiol in vitro. However, the activity of plant UGT71G1 is not high enough in vivo for detoxifying SN-38 by oral delivery of the plant UGT71G1 overexpressing bacteria into mouse. We propose to develop more active UGTs and drug detoxifying bacteria (DDB, using E. coli as the initial model bacteria) for the metabolism of anticancer drug SN-38. We will use two different approaches for searching more active plant UGT71G1 mutants, including rational structure-based UGT design and engineering based on plant Medicago truncatula UGT71G1 structures we determined, and random mutagenesis. We will express and purify UGT mutants and perform enzyme assays to screen for mutants with significantly improved (at least 10-fold increase) catalytic activity on SN
38. We will also screen different E. coli expression systems (vectors) and bacterial strains. The different E. coli expression systems and bacterial strains may behave differently and affect the enzyme activity in mouse. We will identify a suitable E. coli expression system and bacterial strain with respect to its similarity to commensal one in mouse to express the most active plant UGT71G1 mutant(s) against SN-38. Then we will deliver the most active plant UGT71G1 mutant(s) overexpressing bacteria into mouse to determine its ability and activity for metabolizing SN- 38 in vivo and develop drug detoxifying bacteria for the detoxification of SN-38.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bbrep.2020.100893
发表时间:
2021-03
期刊:
Biochemistry and biophysics reports
影响因子:
2.7
作者:
[Jones LB, Wang X, Gullapalli JS, Kunz DA]
通讯作者:
Kunz DA
STRUCTURAL AND MECHANISTIC STUDIES OF XYLOGLUCAN XYLOSYLTRANSFERASE
-
批准号:8362427
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2011
-
负责人:Xiaoqiang Wang
-
依托单位:
海外基金